Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea

K.H. Yoo, K.S. Jung, Y.I. Hwang, Y.B. Park, S.Y. Lee, S.H. Jang, J.H. Kim, D.G. Kim, Y.D. Lee (Seoul, Pyung Chon, Republic Of Korea)

Source: Annual Congress 2012 - Epidemiology of asthma
Session: Epidemiology of asthma
Session type: Thematic Poster Session
Number: 3952
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K.H. Yoo, K.S. Jung, Y.I. Hwang, Y.B. Park, S.Y. Lee, S.H. Jang, J.H. Kim, D.G. Kim, Y.D. Lee (Seoul, Pyung Chon, Republic Of Korea). Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea. Eur Respir J 2012; 40: Suppl. 56, 3952

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003

Characterization of adults with asthma per GINA treatment steps
Source: International Congress 2019 – Epidemiology, genetics, air pollution and sleep
Year: 2019

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016


SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4
Source: International Congress 2016 – Asthma management
Year: 2016

Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017


BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012

10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018

The application of GINA guidelines results in a reduced number of exacerbations in asthmatic patients
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

Effect of allergic sensitization on clinical course of patients with COPD in the Hokkaido COPD cohort study
Source: International Congress 2014 – COPD physiopathology
Year: 2014

Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Effect of tralokinumab on GINA control in severe, uncontrolled asthma
Source: International Congress 2017 – Asthma: mechanisms and treatment
Year: 2017


Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study
Source: Annual Congress 2013 –Disease control and quality of life in airway diseases
Year: 2013


Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
Source: ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017
Year: 2017



Uncontrolled asthma on GINA step 4-5 treatment increases healthcare utilization – report from the population-based OLIN-studies
Source: International Congress 2019 – Nursing care across the spectrum of respiratory illnesses
Year: 2019

P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016

Asthma control test (ACT) in outpatients and hospitalized patients with bronchial asthma
Source: Annual Congress 2009 - Asthma and comorbid conditions
Year: 2009


Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015

The parameters that may affect inhalation therapy success in elderly COPD and asthma patients
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015


‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of asthma . A comparative study
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014